Skip to Content
Merck
All Photos(1)

Documents

AP112P

Sigma-Aldrich

Goat Anti-Human IgG Antibody, HRP conjugate

Chemicon®, from goat

Synonym(s):

Anti-Human IgG HRP Conjugate

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.46

biological source

goat

Quality Level

conjugate

peroxidase conjugate

antibody form

affinity isolated antibody

antibody product type

secondary antibodies

clone

polyclonal

form

lyophilized

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
western blot: suitable

isotype

IgG

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

General description

Immunoglobulin G (IgG) belongs to the immunoglobulin family and is a widely expressed serum antibody. It is a glycoprotein and mainly helps in immune defense. About 70 percent of the total immunoglobulin consists of IgG. IgG is a monomeric immunoglobulin, made up of four polypeptide chains. It consists of two 50 kDa heavy chains (gamma) and two 25kDa light chains. These chains are inter-linked by di-sulfide bonds. Each molecule has two antigen binding sites. IgG is the most abundant immunoglobulin. It is approximately equally distributed in blood and in tissue liquids, constituting 75% of serum immunoglobulins in humans. There are 4 subclasses: IgG1 (66%), IgG2 (23%), IgG3 (7%) and IgG4 (4%).

Specificity

The antibody reacts with the heavy chains of human IgG and with the light chains common to most human immunoglobulins.

Immunogen

Prepared from purified human IgG.

Application

Goat Anti-Human IgG Antibody, HRP conjugate has been used:
  • to detect the bound immunoglobulin G (IgG) in enzyme-linked immunosorbent assay (ELISA) assay
  • in immunohistochemistry or cytochemistry at a dilution of 1:500 - 1:5,000
  • for western blotting with chromogenic substrates at a dilution of 1:5,000 - 1:100,000 and with ECL substrates at a dilution of 1:10,000 - 1:200,000.
  • for EIA at a dilution of 1:5,000-1:100,000

Biochem/physiol Actions

Immunoglobulin G (IgG) participates in hypersensitivity type II and type III. It initiates the classical pathway of the complement system and also neutralizes virus particles and toxins. Maternal IgG can pass through the human placenta to fetus providing immune defense for the neonate against infections. It facilitates antibody-dependent cell-mediated cytotoxicity (ADCC). IgG is digested by papain to produce fragment antigen-binding (Fab). Pepsin digestion of IgG results in the formation of fragment crystallizable (Fc). IgG levels in severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infected patients may be useful to evaluate the severity and prognosis of coronavirus disease 2019 (COVID-19).

Physical form

Purified by immunoaffinity chromatography using antigen coupled to agarose beads. Lyophilized. Buffer is 0.01 M Sodium Phosphate, 0.25 M NaCl, pH 7.6 with 15 mg/mL BSA. Contains no preservative.

Storage and Stability

Maintain lyophilized product at 2°-8°C for up to 12 months from date of receipt. After reconstitution the product is stable for six weeks at 2°-8°C as an undiluted liquid. Reconstitute vial with 2 mL of distilled water. For extended storage after reconstitution, add an equal volume of glycerol to make a final concentration of 50% glycerol followed by storage at -20°C in undiluted aliquots for up to 12 months. Please note the concentration of antibody (and buffer salts) will decrease to one-half of the original after the addition of glycerol and final working dilutions must be adjusted accordingly. Avoid repeated freeze thaw cycles.

WARNING:
Use of sodium azide as a preservative will substantially inhibit the enzyme activity of HRP.

Other Notes

Research Category: Secondary & Control Antibodies
Research Sub Category
Whole Immunoglobulin Secondary Antibodies

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The impact of timing of maternal influenza immunization on infant antibody levels at birth
Zhong Z, et al.
Clinical and Experimental Immunology, 195(2), 139-152 (2019)
Sun Woo Lim et al.
The Korean journal of internal medicine, 37(5), 1031-1049 (2022-06-21)
We previously proposed minicircle vector technology as the potential platform for the development and production of new biologics. In this study, we have designed a novel target molecule for the treatment of allograft rejection and evaluated its feasibility as the
Claudia Tapia-Alveal et al.
Communications biology, 3(1), 781-781 (2020-12-19)
Multiple myeloma (MM) is a neoplasm of plasma cells that secrete patient specific monoclonal immunoglobulins. A recognized problem in MM treatment is the early recognition of minimal residual disease (MRD), the major cause of relapse. Current MRD detection methods (multiparameter
Kyle E Korolowicz et al.
Cells, 10(9) (2021-09-29)
Current treatment options for patients infected with hepatitis B virus (HBV) are suboptimal, because the approved drugs rarely induce cure due to the persistence of the viral DNA genome in the nucleus of infected hepatocytes, and are associated with either
Sun Woo Lim et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 33(10), 10889-10901 (2019-07-04)
Synthetic biologic drugs are highly successful for induction therapy in transplantation, but the development of novel biologics is limited because of the high cost of synthesis and purification. In this study, we developed a novel strategy for the production of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service